Oncology Nursing News®

Blood Cancers

FDA Approves Zanubrutinib for MCL Treatment

FDA Approves Zanubrutinib for MCL Treatment

BY CONOR KILLMURRAY

Challenges In AML Treatment

Challenges In AML Treatment

BY PINKAL DESAI, MD

Moving Towards Precision Medicine in MCL

Moving Towards Precision Medicine in MCL

BY NICHOLE TUCKER

RMAT Designation Granted to CT053 CAR T-Cell Therapy By FDA

RMAT Designation Granted to CT053 CAR T-Cell Therapy By FDA

BY GINA COLUMBUS

Utilizing MRD To Treat Patients With Hairy Cell Leukemia

Utilizing MRD To Treat Patients With Hairy Cell Leukemia

BY CONOR KILLMURRAY

Expert Identifies Potential Biomarkers for Hairy Cell Leukemia

Expert Identifies Potential Biomarkers for Hairy Cell Leukemia

BY JAMES BLACHLY, MD

Measurable Residual Disease's Role in the Relapse Setting

Measurable Residual Disease's Role in the Relapse Setting

BY FRAHAD RAVANDI-KASHANI, MD

Addressing the Unmet Needs of Patients with Hairy Cell Leukemia

Addressing the Unmet Needs of Patients with Hairy Cell Leukemia

BY KERRY ROGERS, MD

Expert Discusses the Safety of Vemurafenib

Expert Discusses the Safety of Vemurafenib

BY AGNIESZKA JANUS, MD, PHD

Managing Toxicities Of Moxetumomab Pasudotox

Managing Toxicities Of Moxetumomab Pasudotox

BY ROBERT J. KREITMAN, MD

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.